Tamicov.

We’ve still no study to hang our hats on, but we do have an announcement. According to an NIH statement on its ongoing study, among over 1K enrollees, randomization to remdesivir rather than placebo for the treatment of COVID-19 significantly hastened time to recovery (15 → 11 days) and numerically improved mortality (12 → 8%). | NIH 2020